The company's low P/S ratio may be due to its receding revenue and the market's belief that the recent revenue performance isn't good enough to keep up with the industry. If recent medium-term revenue trends continue, it's hard to see the share price experience a reversal of fortunes anytime soon.
共同药业股票讨论区
暂无评论